Jazeta

Sitagliptin Hydrochloride, the active ingredient in Jazeta, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults when combined with diet and exercise.

GNH USA supplies Jazeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to global quality standards and provides regulatory support for cross‑border distribution.

Jazeta (sitagliptin) is used to improve glycaemic control in the type 2 diabetes mellitus therapeutic pathway. - Type 2 diabetes mellitus: Improves blood glucose levels when used with diet and exercise. - Combination therapy: Added to metformin or other antidiabetic agents to achieve target HbA1c. - Monotherapy: Can be prescribed alone for patients inadequately controlled on lifestyle measures.

Adverse reactions reported with sitagliptin are generally mild, but serious events can occur.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain. - Upper respiratory tract infection: symptoms of cough and congestion. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: rare skin blistering disorder.

Before prescribing Jazeta, clinicians should consider several safety aspects. - Renal function: assess creatinine clearance and adjust dose if necessary. - Hepatic function: monitor liver enzymes in patients with liver disease. - Cardiovascular disease: use with caution in patients with unstable heart conditions. - History of pancreatitis: avoid use in individuals with prior pancreatitis episodes. - Pregnancy and lactation: evaluate risk‑benefit ratio before use. - Store at ambient temperature: keep in original container, protect from moisture and light.

Sitagliptin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Insulin: increased risk of hypoglycaemia. - Sulfonylureas: heightened hypoglycaemia potential. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise sitagliptin exposure.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor renal function and potassium levels. - Diuretics: watch for dehydration and electrolyte imbalance. - Warfarin: periodic INR checks are advised.